Lifecore Biomedical, Inc. — Earnings Quality Grade F
LFCR · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 74 days, change -8 days YoY
AR growth -8.8% vs revenue growth 0.5%
Revenue 0.5%, CFFO -180.2%. Cash follows revenue
Expense Quality
Inventory -9.9% vs COGS 2.5%. Normal
CapEx growth -27.1% vs revenue 0.5%. Normal
SG&A/Gross Profit = 109.3%, exceeds 70%
Gross margin 31.3%, change -1.4pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.0B)
Accruals ratio = -16.6%. Low accruals
Cash $0.0B covers only 12% of debt $0.1B
Balance Sheet Health
Goodwill+Intangibles $0.0B = -98% of equity. Manageable
Interest coverage = -0.5x (<2x). Financial stress
Other assets -19.3% vs revenue 0.5%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
Goodwill+Intangibles change -23% YoY. Normal
Manipulation Score
M-Score = -3.37 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25